A Beacon in the Dark: Canakinumab. A New Therapeutic Perspective in Chronic Tophaceous Gout
Crossref DOI link: https://doi.org/10.1007/s40744-018-0104-8
Published Online: 2018-03-09
Published Print: 2018-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Marotto, Daniela
De Santis, Antonella
Chessa, Donatella
Firinu, Davide
Del Giacco, Stefano
Funding for this research was provided by:
Novartis Farma
Text and Data Mining valid from 2018-03-09
Article History
Received: 14 December 2017
First Online: 9 March 2018